# Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

> **NCT03031444** · PHASE2,PHASE3 · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 135 (actual)

## Conditions studied

- Colorectal Cancer Stage IV
- Metastasis

## Interventions

- **DRUG:** Cetuximab plus FOLFIRI/FOLFOX
- **DRUG:** FOLFIRI/FOLFOX/CapeOX

## Key facts

- **NCT ID:** NCT03031444
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2021-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031444, "Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03031444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*